EGFR mutation and response of lung cancer to gefitinib

N Engl J Med. 2005 May 19;352(20):2136; author reply 2136. doi: 10.1056/NEJM200505193522019.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • Carcinoma, Non-Small-Cell Lung / drug therapy
  • Carcinoma, Non-Small-Cell Lung / genetics*
  • Drug Resistance, Neoplasm / genetics*
  • ErbB Receptors / genetics*
  • Female
  • Gefitinib
  • Genotype
  • Humans
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / genetics*
  • Point Mutation*
  • Quinazolines / therapeutic use

Substances

  • Antineoplastic Agents
  • Quinazolines
  • ErbB Receptors
  • Gefitinib